NanoSyrinx: Newsroom

NanoSyrinx at Number 10

Our CEO Joe Healey was invited to Number 10 this week, to discuss the future of Engineering Biology in the UK as part of a networking and investment breakfast. Synthetic biology or “Engineering Biology” has been highlighted as one of the five key technology areas for the UK’s future economy. Understanding how best to incubate, […]

JPM week 2024: NanoSyrinx highlighted in GEN

NanoSyrinx CEO Joe Healey, and CBO James Lapworth attended the JP Morgan Healthcare conference in San Francisco last week. Among a great week of meetings with collaborators, investors and partners, they sat down with Jonathan Grinstein PhD, a writer for GEN Edge, and spoke about the journey the company had been on and the outlook […]

NanoSyrinx appoints Anthony Johnson as Non-Executive Director

Coventry, UK, 10 November 2023: NanoSyrinx, a synthetic biology company developing a novel platform for targeted intracellular delivery of biologic therapeutics, today announced Anthony Johnson, M. D., has joined its Board as Non-Executive Director. Tony’s appointment forms part of the Company’s ongoing strategy to expand and strengthen its leadership team as the Company prepares for […]

NanoSyrinx to feature in PwC’s Life Sciences Future50 Report

We are delighted to be showcased as one of the 50 companies in PwC UK’s ‘Life Sciences Future 50’ report, illustrating the world-class science and innovation being led by the UK’s life sciences sector to solve some of the most important challenges in scientific research and human healthcare. Find out more here: https://bit.ly/3Fnw379

NanoSyrinx in Parliament

Our Founder and CEO, Joe Healey, was invited by the Parliamentary and Scientific Committee (P&SC – https://www.scienceinparliament.org.uk/) to discuss the future and potential of Synthetic Biology for the UK and for human health. The UK has a stated (and laudable) ambition to become a “Scientific Superpower”, and Synthetic Biology is intimately tied to that vision. […]

NanoSyrinx featured by Spin-up Science on YouTube

Ben Miles at Spin-up Science took time recently to feature NanoSyrinx in their latest YouTube video. Follow the links below to learn how what NanoSyrinx is developing could, in Ben’s words, “change medicine forever”. You can also hear more from the discussion on the Scientist-to-CEO podcast Ben runs, which is available here: Spin up Science […]

NanoSyrinx named as winner of the 2022 AbbVie UK Golden Ticket programme

NanoSyrinx has been named as the winner of the 2022 AbbVie UK Golden Ticket accelerator programme. The 2022 AbbVie UK Golden Ticket is a competitive award, open to early-stage life sciences companies and biotech start-ups that are working to develop cutting-edge therapies or technology platforms. Under the programme, the company will benefit from: One year […]

NanoSyrinx featured in Drug Discovery News

NanoSyrinx’s CEO Joe Healey and academic co-founder Nick Waterfield have been interviewed by Drug Discovery News. In the article, they discuss the surprising origins and future potential of our nanosyringe technology. Read all about it here: https://www.drugdiscoverynews.com/bacterial-nanosyringes-are-drug-and-delivery-all-in-one-15451

NanoSyrinx wins award for “Best Innovation”

NanoSyrinx has been recognised by winning the award for Best Innovation at the ICURe Celebration & Showcase event, held at County Hall, London 22nd March 2022. The award panel, comprised of innovators and early-stage investors, recognised the groundbreaking nature of the company’s technology and commented on its potential to have a significant impact on the […]

Dr Marie McAvoy joins NanoSyrinx as Chief Scientific Officer

NanoSyrinx, a biotech company using synthetic biology approaches to develop a new modality for the targeted intracellular delivery of biologic therapeutics, has strengthened its management team with the appointment of Dr Marie McAvoy as its Chief Scientific Officer. Dr McAvoy joins NanoSyrinx from GSK where she was Senior Director in the Oncology Cell Therapy Research […]

James Lapworth joins NanoSyrinx as Chief Business Officer

Dr James Lapworth has joined the NanoSyrinx management team as Chief Business Officer to support the company in delivering its ambitious plans following the recent announcement of our oversubscribed Seed+ funding round. James is an experienced business development and technology commercialisation professional with over 10 years’ experience in fundraising, developing, partnering and out-licensing new technologies, […]

NanoSyrinx announces oversubscribed £6.2M Seed+ funding round to develop its novel biologic delivery platform

NanoSyrinx has raised a further £6.2m of seed financing, co-led by incoming Octopus Ventures and existing investor M Ventures (Amsterdam, The Netherlands), the corporate venture capital arm of Merck KGaA. Previous investors BioCity and the UK Innovation & Science Seed Fund (UKI2S) joined the funding round along with experienced deeptech investor IQ Capital and Jonathan […]

NanoSyrinx co-founder Nick Waterfield appointed as Professor at Warwick Medical School

The whole NanoSyrinx team would like to congratulate our co-founder Nick Waterfield on his recently announced promotion to full Professor at the University of Warwick Medical School. This is a richly deserved appointment as Prof. Waterfield’s track record in molecular microbiology is substantial. With particular emphasis on bacterial toxicology and the adaptations required for benign […]

NanoSyrinx appoints Jane Dancer to the Board as a new NED

NanoSyrinx is delighted to announce that Jane Dancer has agreed to join the Board and is bringing with her a wealth of business development and strategic knowledge for driving value from platform companies. Jane is a well-known figure in the sector, having served as CBO at F-Star, Cambridge Antibody Technologies, as well as VP for […]

NanoSyrinx announces closure of its Pre-Seed investment round

The team at NanoSyrinx are delighted to announce our pre-seed financing with an excellent board of investors: MVentures, BioCity and UKI2S. Our seed round is helping us deliver key scientific milestones as we look to create a revolution in the delivery of biologic molecules in the cell and gene therapy and conventional therapeutic space. NanoSyrinx […]

Meet us at BioTrinity!

NanoSyrinx is breaking radio silence, and will be pitching at BioTrinity 2019! If you’re interested in hearing more from us, connect with us on the partneringONE app, pull us aside at the event for a coffee, or come along at 11.15 on Wednesday 1st to see a taster of what we’ve been working on in […]